Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPOR | P19235 | 4/20 | 0.42 |
| ▸ | ANPEP | P15144 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 2/20 | 0.37 |
| ▸ | MMP2 | P08253 | 2/20 | 0.36 |
| ▸ | MMP9 | P14780 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.36 |
| ▸ | TLR2 | O60603 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.34 |
| ▸ | LTA4H | P09960 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4738904 | 1.00 | EPOR (0.42) | EPORANPEPF2MMP2MMP9 | |
| SCHEMBL8893033 | 0.94 | CYP1A2 (0.37) | EPORCYP1A2TSHR | |
| SCHEMBL8892535 | 0.94 | CYP1A2 (0.37) | EPORCYP1A2TSHR | |
| Trifluoroacetic Acid SCHEMBL4359902 | 0.94 | EPOR (0.38) | EPORANPEPF2MMP2MMP9 | |
| Trifluoroacetic Acid SCHEMBL4355575 | 0.91 | EPOR (0.36) | EPORANPEPF2TLR2DPP7 | |
| SCHEMBL25182246 | 0.91 | PRSS1 (0.37) | TLR2 | |
| SCHEMBL25179548 | 0.89 | CYP1A2 (0.34) | EPORCYP1A2TSHR | |
| SCHEMBL1000116 | 0.89 | BCHE (0.37) | CYP1A2TSHR | |
| SCHEMBL1000114 | 0.89 | BCHE (0.37) | CYP1A2TSHR | |
| SCHEMBL8158096 | 0.89 | BCHE (0.37) | CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1718340-B1 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | BAYER SCHERING PHARMA AG (DE) | 2007-11-21 | — | — | EP | disclosed |
| EP-1718340-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | Schering AG (DE) | 2006-11-08 | — | — | EP | disclosed |
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | SCHERING AG (DE) | 2005-10-20 | — | — | US | disclosed |
| WO-2005074901-A2 | NEW EFFECTOR CONJUGATES, PROCESS FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE | SCHERING AG (DE) | 2005-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234247-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | EPOR 1/4885ANPEP 949/4885F2 1270/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.